Investors interested in Medical stocks should always be looking to find the best-performing companies in the group. Is Agilon Health (AGL) one of those stocks right now? Let's take a closer look at the stock's year-to-date performance to find out.
Agilon Health is a member of the Medical sector. This group includes 917 individual stocks and currently holds a Zacks Sector Rank of #11. The Zacks Sector Rank considers 16 different groups, measuring the average Zacks Rank of the individual stocks within the sector to gauge the strength of each group.
The Zacks Rank is a proven system that emphasizes earnings estimates and estimate revisions, highlighting a variety of stocks that are displaying the right characteristics to beat the market over the next one to three months. Agilon Health is currently sporting a Zacks Rank of #2 (Buy).
The Zacks Consensus Estimate for AGL's full-year earnings has moved 17.2% higher within the past quarter. This is a sign of improving analyst sentiment and a positive earnings outlook trend.
Based on the latest available data, AGL has gained about 384.4% so far this year. Meanwhile, the Medical sector has returned an average of -0.7% on a year-to-date basis. This means that Agilon Health is outperforming the sector as a whole this year.
One other Medical stock that has outperformed the sector so far this year is CRISPR Therapeutics AG (CRSP). The stock is up 3% year-to-date.
In CRISPR Therapeutics AG's case, the consensus EPS estimate for the current year increased 8.7% over the past three months. The stock currently has a Zacks Rank #2 (Buy).
Breaking things down more, Agilon Health is a member of the Medical Services industry, which includes 70 individual companies and currently sits at #105 in the Zacks Industry Rank. On average, this group has gained an average of 2.7% so far this year, meaning that AGL is performing better in terms of year-to-date returns.
In contrast, CRISPR Therapeutics AG falls under the Medical - Biomedical and Genetics industry. Currently, this industry has 449 stocks and is ranked #178. Since the beginning of the year, the industry has moved +1.3%.
Agilon Health and CRISPR Therapeutics AG could continue their solid performance, so investors interested in Medical stocks should continue to pay close attention to these stocks.
Zacks' Research Chief Names "Stock Most Likely to Double"
Our team of experts has just released the 5 stocks with the greatest probability of gaining +100% or more in the coming months. Of those 5, Director of Research Sheraz Mian highlights the one stock set to climb highest.
Of course, all our elite picks aren't winners, but this one could far surpass earlier Zacks' Stocks Set to Double like D-Wave Quantum, which shot up +680.1%.
Free: See Our Top Stock And 4 Runners UpWant the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Agilon Health, Inc. (AGL): Free Stock Analysis Report
CRISPR Therapeutics AG (CRSP): Free Stock Analysis Report
This article originally published on Zacks Investment Research (zacks.com).